Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental T-Cell therapy enters human testing for Tough-to-Treat blood cancers

NCT ID NCT05424822

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

Summary

This is the first human study of an experimental drug called JNJ-80948543, designed to redirect a patient's own immune T-cells to attack cancer cells. It is enrolling 167 adults with advanced non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or stopped responding to other treatments. The main goals are to find a safe dose, understand side effects, and see if the treatment shows early signs of helping to control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aichi Cancer Center

    Nagoya, 464 8681, Japan

  • Aidport Sp z o o

    Skorzewo, 60-185, Poland

  • CHRU de Lille Hopital Claude Huriez

    Lille, 59037, France

  • Carmel Medical Center

    Haifa, 34362, Israel

  • Chongqing University Cancer Hospital

    Chongqing, 400044, China

  • City of Hope

    Duarte, California, 91010, United States

  • Hadassah Medical Center

    Jerusalem, 9112001, Israel

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Institut Curie

    Paris, 75005, France

  • Institut Universitaire du cancer de Toulouse-Oncopole

    Toulouse, 31059, France

  • Institut de Cancerologie Strasbourg Europe ICANS

    Strasbourg, 67033, France

  • Linear Clinical Research Ltd

    Nedlands, 6009, Australia

  • Macquarie University Hospital

    Macquarie University, 2109, Australia

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • National Cancer Center Hospital East

    Kashiwa, 277 8577, Japan

  • Odense University Hospital

    Odense, 5000, Denmark

  • Rigshospitalet

    Copenhagen, 2100, Denmark

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • Scientia Clinical Research

    Randwick, 2031, Australia

  • Seattle Cancer Care Alliance

    Seattle, Washington, 98109, United States

  • Sun Yat Sen University Cancer Center

    Guangzhou, 510060, China

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, 64239, Israel

  • Texas Transplant Institute

    San Antonio, Texas, 78229, United States

  • The Alfred Hospital

    Melbourne, 3004, Australia

  • The Cancer Institute Hospital of JFCR

    Tokyo, 135 8550, Japan

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Tianjin cancer hospital

    Tianjin, 300060, China

  • Union Hospital Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, 430030, China

  • Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz

    Gdansk, 80 214, Poland

Conditions

Explore the condition pages connected to this study.

LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL LYMPHOMA, NON-HODGKIN